Prevention of recurrent thrombosis in the antiphospholipid antibody syndrome: How long and how high with oral anticoagulant therapy?

Medical Journal of Australia

Volumn 180, Issue 9, 2004, Pages 436-437

  Baker, Ross I ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BLEEDING; BLOOD CLOTTING TEST; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG FATALITY; EDITORIAL; HUMAN; IMMUNOASSAY; LUNG EMBOLISM; RECURRENCE RISK; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; SEROLOGY; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

EID: 2442448505     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06015.x     Document Type: Editorial

References (11)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
2. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 931-942.
3. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-1353.
4. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
5. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid antibody syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
6. Schulman S, Svenungsson E, Granqvist S, et al. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-338.
7. Health Insurance Commission. Medicare Benefits Schedule (MBS) item statistics reports. MBS statistics 2002-2003. Available at: www.hic.gov.au/statistics/dyn_mbs/forms/mbs_tab4.shtml (accessed Feb 2004).
8. Khamashta MA, Cuadrado MJ, Loizou S, et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332: 993-997.
9. Roseve MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308.
10. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-428.
11. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.